NAT16
Probable N-acetyltransferase 16
Also known as: C7orf52, FLJ39237, NAT16_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q8N8M0
- Gene
- NAT16
- Ensembl
- ENSG00000167011
- Chromosome
- 7
- Canonical length
- 369 aa
- Protein class
- Metabolic proteins, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm
OverviewNCBI Gene
Predicted to enable acyltransferase activity, transferring groups other than amino-acyl groups. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
369 residues, UniProt reviewed canonical sequence.
>Q8N8M0|NAT16
1 MKLEASCGTA TSEVPKPEKK TARDAEPSSE TRPQEVEAEP RSGSGPEAEA EPLDFVVATE
61 REFEEVLAIS GGIYGGLDYL PSRYHSWLRD PDRTVVLAKR NGGVIALESV NVIDAGETVL
121 VEGLRVAPWE RGKGVAGLLQ RFCSQLVKRQ HPGVKVARLT RDDQLGPREL KKYRLITKQG
181 ILLVRFNASA LLAGLGARLA ALRTSGTFSP LPTEAVSEAG GDVARLLLSP SVQRDVLPGG
241 TIIQDWQPYR PSESNLRLLA AKGLEWRVDS RARPRVLTLC TRPFPIPHGG DGTWRYLNID
301 AFGSDGAQVQ SQLLWHLQRQ APRLVGLNVM CQLFLEPQLW SQLADFCQVG LGLELVKGYT
361 EQYLLEADILocalizationUniProt · AlphaFold · HPA
Whether an antibody against NAT16 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Unknown
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.31
- Highest tissue expression
- 6.4 nTPM
Expression across tissuesHPA
Tissue
- retina: 6.4 nTPM
- basal ganglia: 4.5 nTPM
- pituitary gland: 3.5 nTPM
- hypothalamus: 2.8 nTPM
- cerebral cortex: 2.7 nTPM
- pancreas: 2.2 nTPM
Single-cell type
- retinal horizontal cells: 238 nCPM
- pancreatic islet cells: 12 nCPM
- retinal amacrine cells: 5.7 nCPM
- corticotrophs: 5.1 nCPM
- oligodendrocyte progenitor cells: 4.8 nCPM
- other brain neurons: 4.4 nCPM
Immune cell
- neutrophil: 0.3 nTPM
- naive B-cell: 0.1 nTPM
- NK-cell: 0.1 nTPM
- plasmacytoid DC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
Brain region
- hypothalamus: 8.8 nTPM
- cerebral cortex: 8.6 nTPM
- thalamus: 8.4 nTPM
- amygdala: 6 nTPM
- basal ganglia: 5.6 nTPM
- midbrain: 5.4 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.5
- gnomAD pLI
- 0
- gnomAD missense Z
- -0.25
- DepMap mean gene effect
- -0.05
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Molecular functions
- transferring groups other than amino-acyl groups
- acyltransferase activity
Protein domainsUniProt · Pfam · InterPro
- GNAT domain
- Acyl-CoA N-acyltransferase
- Acetyltransferase (GNAT) family
- Histidine N-acetyltransferase, C-terminal
- Histidine N-acetyltransferase, C-terminal
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads NAT16 as an antibody target. Whether an autoantibody or antibody against NAT16 could matter depends on whether native NAT16 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
NAT16 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label NAT16 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...